Date: 2014-06-10
Type of information: Results
phase: preclinical
Announcement: preclinical results
Company: Adocia (France)
Product: BioChaperone® Lispro U300 (ultra-fast acting formulation of insulin Lispro - Humalog®)
Action
mechanism: BioChaperone® Lispro U300 is an ultra-concentrated prandial insulin.
Disease: diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On June 10, 2014, Adocia announced positive preclinical results for its concentrated formulation of insulin lispro, BioChaperone Lispro U300. The study showed that BioChaperone Lispro U300 had a faster onset of action than Humalog® (Eli Lilly) at 100 IU/mL. Adocia\'s concentrated formulation uses the proprietary technology BioChaperone® which succeeds in accelerating the absorption of prandial insulins and which has already been used in two products currently in clinical development (BioChaperone Lispro and HinsBet®).The preclinical data show BioChaperone Lispro U300 has an ultra-fast action compared to Humalog U100, equivalent to the one obtained with BioChaperone Lispro U100. In this preclinical cross-over study, BioChaperone Lispro U300 was compared to Humalog in a model established and correlated to human. This correlation was based on the phase 2 BioChaperone Lispro clinical results. The comparison of the pharmacodynamics and pharmacokinetics of BioChaperone Lispro U300 and Humalog demonstrated a faster action for BioChaperone Lispro U300, despite the increased concentration. A phase 1/2 clinical study with BioChaperone Lispro U300 is scheduled for the first half of 2015. The BioChaperone technology for prandial insulin is protected by six families of patents valid for some of them until 2033.
